Ser154
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser154  -  MEKK1 (human)

Site Information
RAPAAEPsPAAAPAG   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 4269877

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 )
Disease tissue studied:
lung cancer ( 4 ) , non-small cell lung cancer ( 4 )
Relevant cell line - cell type - tissue:
HeLa (cervical) ( 1 ) , HeLa S3 (cervical) ( 3 ) , HeLa_Meta (cervical) ( 2 ) , HeLa_Pro (cervical) ( 2 ) , HeLa_Telo (cervical) ( 2 ) , lung ( 4 )

Upstream Regulation
Treatments:
MG132_withdrawal ( 2 ) , nocodazole ( 3 ) , thymidine ( 3 )

References 

1

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

2

Dulla K, et al. (2010) Quantitative site-specific phosphorylation dynamics of human protein kinases during mitotic progression. Mol Cell Proteomics 9, 1167-81
20097925   Curated Info

3

Daub H, et al. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31, 438-48
18691976   Curated Info

4

Rikova K (2007) CST Curation Set: 3149; Year: 2007; Biosample/Treatment: tissue, lung/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info